REGN•benzinga•June 2, 2025 at 11:08 AM

Regeneron Pharmaceutical Announced A Strategic In-licensing Agreement With Hansoh Pharmaceuticals Group Company Limited To Acquire Exclusive Clinical Development And Commercial Rights Outside Of The Chinese Mainland, Hong Kong And Macau For A Dual Glp-1/G

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 2, 2025 by benzinga